Biopharma financings accelerated in the first half of 2026, with total funding reported at $59.76 billion across 567 deals—more than double the $29.53 billion raised in H1 2025. The year-over-year jump was driven largely by follow-on financings, which accounted for roughly half of the total. June activity totaled $10.32 billion across 99 transactions, compared with $10.71 billion across 103 deals in May and $13.21 billion across 101 deals in April. The data points to a thaw driven by investors adding to existing positions rather than solely funding early-stage bets. For biotech operators, the shift can translate into improved access to capital for late-stage and de-risking programs, with deal structures more likely to reflect post-traction milestones.